Received Jun 15, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | 2 | UNK | — |
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | 1 | UNK | — |
Suspected vaccination failure; Internal shingles; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingles vaccine) solution for injection for prophylaxis. On an unknown date, the patient received the 2nd dose of Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced vaccination failure (Verbatim: Suspected vaccination failure) (serious criteria GSK medically significant) and zoster sine herpete (Verbatim: Internal shingles).The outcome of the vaccination failure and zoster sine herpete were not reported. It was unknown if the reporter considered the vaccination failure and zoster sine herpete to be related to Shingles vaccine. The company considered the vaccination failure to be unrelated to Shingles vaccine. Additional Information: GSK Receipt Date: 11-JUN-2026 This case was reported by a patient via interactive digital media. The patient has had both shingles vaccines and still got them. The patient developed internal shingles. This case was considered as vaccination failure as details regarding time to onset and laboratory confirmation regarding shingles were unknown at the time of reporting. The batch number was not provided, and we are unable to contact the reporter.; Sender's Comments: A case of Vaccination failure, on an unknown time after vaccination with the 1st and 2nd dose of Shingles vaccine, in a patient. Based on the available information a possible causality that the event was caused by GSK vaccine product cannot be ascertained. Consent for further follow up has not been received.